Page 11 - FLIPBOOK

Study design

• Retrospective, real world data analysis from 2007 to 2016 of 22,860 patients with

PCa receiving >2 injections of an LHRH agonist and >1 measurement

of PSA or T.

• All LHRH agonists i.e. leuprolide acetate (intramuscular or subcutaneous), triptorelin

and goserelin were grouped together for analysis

• Analyses used 2 definitions of month for 1, 3, 4 and 6-month

formulations respectively:

1) 28-day Month (late dosing was after day 28, 84, 112 or 168)

2) Extended Month (late dosing was after day 32, 97, 128 or 194) – likely consistent with

usual scheduling in clinical practice

• Frequencies of late dosing, associated T values and rates of
T and PSA testing were captured.

SOURCE: Crawford E.D. et al.,The Journal of Urology. Vol. 203, 743-750, April 2020.